Alessandro Testori — ASN Events

Presentations this author is a contributor to:

Four-year survival update for metastatic melanoma (MM) patients (pts) treated with ipilimumab (IPI) + dacarbazine (DTIC) on phase 3 study CA184-024 (#711)